Production of 230 Pa by proton irradiation of 232 Th at the LANL isotope production facility: Precursor of 230 U for targeted alpha therapy

Uranium-230 (t  = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope Pa (t  = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary Pa production runs were performed at the Los Alamos N...

Full description

Saved in:
Bibliographic Details
Published in:Applied radiation and isotopes 2020-02, Vol.156, p.108973
Main Authors: Friend, Mitchell T, Mastren, Tara, Parker, T Gannon, Vermeulen, Christiaan E, Brugh, Mark, Birnbaum, Eva R, Nortier, F Meiring, Fassbender, Michael E
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Uranium-230 (t  = 20.8 d) is an alpha-emitting radionuclide that has potential application in targeted alpha therapy (TAT) of cancer. Its parent isotope Pa (t  = 17.4 d), can be produced by proton irradiation of thorium metal targets. Preliminary Pa production runs were performed at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) using thin thorium metal targets and a proton beam energy of 15-30 MeV, followed by radiochemical separation of Pa from the irradiated target matrix. The measured Pa production yields were found to exceed the predicted values in most of the experiments that were performed. This data will inform further production efforts for providing Pa/ U for clinical trials.
ISSN:1872-9800